Among patients with chronic obstructive pulmonary disease who received prior treatment with multiple-inhaler triple therapy, single-inhaler triple therapy was effective in improving health status and ...

Selecting appropriate inhalers based on individual characteristics and shared decision-making is crucial for optimizing care for patients with COPD. Jeffrey D. Dunn ...

Please provide your email address to receive an email when new articles are posted on . The single inhaler combined budesonide, glycopyrrolate and formoterol fumarate. The risk for cardiopulmonary ...

Inhalers Single-inhaler triple therapy is associated with a favorable benefit-risk profile compared with dual therapy for patients with symptomatic COPD and a history of exacerbations. Single-inhaler ...

Please provide your email address to receive an email when new articles are posted on . Compared with a dual therapy inhaler, a triple therapy inhaler improved inspiratory capacity in those with COPD.

There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic obstructive pulmonary disease (COPD), according to real-world ...

The FDA approved United Kingdom-based GlaxoSmithKline’s Trelegy Ellipta, a once-daily inhaler that contains three medicines for chronic obstructive pulmonary disease. The inhaler, developed with the ...

COPD inhaled triple therapy (BDP/FF/G) improved symptoms, lung function, adherence, and QOL in patients previously treated with inhaled dual therapy.

(HealthDay News) — For patients with chronic obstructive pulmonary disease (COPD), once-daily single-inhaler triple therapy is better for lung function and health-related quality of life than inhaled ...